• (PLX AI) – Hansa Biopharma fell 5% in morning trading after Carnegie analysts cut their price target on the stock to SEK 140 from SEK 190.
  • • Recommendation remains hold
  • • Hansa Biopharma may be seeking to raise additional capital already next year, Carnegie said
  • • Meanwhile, catalysts to accelerate the slow commercial trajectory in the EU remain distant, with no additional data likely in the next 12 months, the analysts said

Quelle: PLX AI